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Abstract
Background: To determine the prevalence and severity of bone deficits in a cohort of childhood cancer survivors
(CCS) compared to a healthy sibling control group, and the modifiable factors associated with bone deficits in CCS.
Methods: Cross-sectional study of bone health in 319 CCS and 208 healthy sibling controls. Bone mineral density
(BMD) was measured by dual-energy x-ray absorptiometry (DXA). Generalized estimating equations were used to
compare measures between CCS and controls. Among CCS, multivariable logistic regression was used to evaluate
odds ratios for BMD Z-score ≤ -1.
Results: All subjects were younger than 18 years of age. Average time since treatment was 10.1 years (range 4.3 -
17.8 years). CCS were 3.3 times more likely to have whole body BMD Z-score ≤ -1 than controls (95% CI: 1.4-7.8; p
= 0.007) and 1.7 times more likely to have lumbar spine BMD Z-score ≤ -1 than controls (95% CI: 1.0-2.7; p = 0.03).
Among CCS, hypogonadism, lower lean body mass, higher daily television/computer screen time, lower physical
activity, and higher inflammatory marker IL-6, increased the odds of having a BMD Z-score ≤ -1.
Conclusions: CCS, less than 18 years of age, have bone deficits compared to a healthy control group. Sedentary
lifestyle and inflammation may play a role in bone deficits in CCS. Counseling CCS and their caretakers on
decreasing television/computer screen time and increasing activity may improve bone health.
Introduction
Osteoporosis is a systemic skeletal disease characterized
by low bone mass and microarchitectural deterioration,
resulting in an increased susceptibility to fracture [1].
Reduced bone mineral density (BMD) is a recognized
condition among childhood cancer survivors (CCS). It is
estimated that up to 46% of CCS less than 18 years old
have reduced BMD [2-8]. Although children usually
recover from fractures without any complication, frac-
tures in adults have been shown to significantly increase
both morbidity and mortality [9,10]. Importantly, the
majority of bone accretion occurs in adolescence and
young adulthood with peak bone mass reached by the
second or third decade [11]. Treatment during adoles-
cence interrupts this critical period of bone acquisition.
A resultant decrease in peak bone mass would be
expected to increase the risk of osteoporosis and osteo-
porotic fractures later in life [12].
The known risk factors for reduced BMD in CCS
include treatment with glucocorticoids [6,13-16], radia-
tion [16-21], methotrexate [2,6,16,18,21], and endocrine
insufficiencies such as growth hormone (GH) deficiency
[5,17,22] and hypogonadism [6,17,23] that are sequelae of
cancer treatment. While efforts are made to limit the
exposure to these agents without compromising their
effectiveness, there are limitations to these approaches
due to the nature of the disease and available treatment
options. Hence, there is a need to identify modifiable risk
factors to design appropriate preventive and therapeutic
interventions during childhood and adolescence while
there is still potential for BMD gain. Currently there are
limited data on modifiable lifestyle factors that could
influence bone health in CCS, therefore we undertook a
study to evaluate the associations between potentially
modifiable factors and bone deficits in CCS. We hypothe-
sized that CCS will have lower BMD compared to the
sibling control group and that low activity, low lean body
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inflammation, and lower dietary calcium, vitamin D and
zinc intake will be associated with bone deficits in CCS.
These data could be used to focus bone health promoting
interventions and by pediatricians during routine health
maintenance visits to guide counseling of CCS on ways
to improve bone health, prevent osteoporosis and reduce
the risk of fractures.
Methods
The study was approved by the Institutional Review
Board: Human Subjects Committee at the University of
Minnesota Medical Center and Children’s Hospitals and
Clinics of Minnesota. Consent (and assent as appropri-
ate) was obtained from children and their parent/guar-
dian(s). We identified 723 living subjects, ages 9-18 years
old, treated for cancer at the University of Minnesota
Amplatz Children’s Hospital and the Children’s Hospitals
& Clinics of Minnesota, in remission and surviving for ≥
5 years after diagnosis of leukemia, central nervous sys-
tem (CNS) tumors and solid tumors. Of these, 66 were
not able to be contacted; of the remaining 657, 319 (49%)
agreed to participate. 110 had leukemia, 127 solid tumors
(i.e. sarcoma, renal, neuroblastoma, non-Hodgkin’sl y m -
phoma), and 82 CNS tumors (i.e. glial tumors, retinoblas-
toma, neuroectodermal tumors). 134 had a history of
corticosteroid treatment, and 74 had a history of treat-
ment with radiation (31 cranial radiation). Participants
treated with hematopoietic cell transplantation (HCT)
were excluded. There were no significant differences in
age, sex, race, diagnosis, age at diagnosis and length of
follow-up (time from diagnosis to study evaluation)
between CCS participants and non-participants. A con-
temporary control group of 208 healthy siblings of CCS
were recruited. Controls known to suffer from chronic
illnesses including hypothyroidism and delayed puberty,
or at risk for GH deficiency (i.e. height > 2 standard
deviation (SD) below the mean and height velocity > 2
SD below the mean) were excluded from participation.
Following a 10-12 hour overnight fast, all participants
underwent a physical examination (including Tanner sta-
ging [24] by a trained study physician), height measured
by wall mounted stadiometer (without shoes) to the near-
est 0.1 cm and weight by electronic scale to the nearest
0.1 kg, and laboratory testing, including free thyroxine
(free T4) by competitive immunoassay (CV 5.8-7.3%),
thyroid stimulating hormone (TSH) (CV 4.9%), follicle
stimulating hormone (FSH) (CV 5.8-6.1%), and insulin-
like growth factor-1 (IGF-1) (CV 5.2-6.4%) by chemilumi-
nescent immunoassay (Siemens Healthcare Diagnostics,
T a r r y t o w n ,N Y ) ;a n di n t e r l e u kin-6 (IL-6) (CV 14.5%) by
ELISA (R&D Systems, Minneapolis, MN), adiponectin
(CV 17.1%) and leptin (CV 13.7%) by 2-plex competitive
immunoassay on the Luminex platform (Austin, TX)
using bead sets from R&D Systems (Minneapolis, MN).
GH stimulation test using clonidine and arginine was
performed. GH deficiency was defined as a stimulated
peak GH level less than 7 mcg/L, which is a more conser-
vative cutoff than 10 mcg/L, which is frequently used in
clinical practice to diagnose GH deficiency [25]. Total
body (not excluding head) BMD, posterior anterior lum-
bar spine (L2-L4), and body composition (percent body
fat and lean body mass) were assessed by dual-energy
x-ray absorptiometry (DXA) (G.E. Lunar Prodigy scan-
ner; pediatric software version 9.3; Madison, WI, USA),
and bone age by the Greulich and Pyle method [26].
Dietary intake was evaluated using the Youth/Adolescent
Questionnaire (YAQ) [27,28]. Physical activity, including
television/computer screen time, was assessed by the
Modifiable Activity Questionnaire for Adolescents [29].
The diagnoses of hypogonadism was made by either par-
ticipant report of a history of diagnosed hypogonadism
or for males an LH > 10 IU/L and testosterone below the
lower end of reference range for pubertal stage and for
females an FSH > 40 IU/L. The diagnosis of hypothyroid-
ism was made by participant report, high TSH (> 5.0 uU/
mL) and normal free T4, or low free T4 (< 0.8 ng/dL).
Height and weight Z-scores were calculated based on
2000 Centers for Disease Control growth charts.
According to current International Society for Clinical
Densitometry (ISCD) recommendation the terms osteo-
porosis should be limited to children with low BMD (Z-
score ≤ -2) accompanied by fractures [30]. Since very few
patients met the definition of osteoporosis or low BMD in
our study, yet a substantial proportion of patients had
BMD below average, we defined a mild BMD deficit as a
Z-score ≤ -1. This cutoff has been used in other studies
describing bone deficits in CCS [22,31]. The rationale for
using this cutoff is that those with lower BMD Z-scores
are likely to remain in the low end of the normal range
[32] and reach a lower peak BMD [11] thus increasing
their lifetime risk of osteoporosis and fracture. In addition,
any decrease in BMD Z- score predisposed children to an
increased risk of fracture [33,34].
Statistical analysis
Descriptive statistics are expressed as frequencies and
percents or mean ± standard error (SE), as appropriate.
Regression models based on generalized estimating equa-
tions (GEE) with robust variance estimates were used to
compare measures between CCS and the sibling control
group with adjustments as noted in tables, to appropri-
ately account for intra-family correlation. Among CCS,
multivariable logistic regression was used to evaluate
odds ratios (OR) for the associations between Z-score ≤
-1 of the whole body BMD and lumbar spine BMD with
the following predictors: age at diagnosis, time since
diagnosis, GH Status (GH deficient, not GH deficient),
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body mass index (BMI), IL-6, adiponectin, leptin, calcium
intake, vitamin D intake, zinc intake, omega-3 intake,
protein intake, milk intake, fruit and vegetable intake,
physical activity score, television/computer screen time,
time elapsed since diagnosis, radiation and steroid expo-
sure. All models were adjusted for sex, age-at-study, eth-
nicity (white-not-Hispanic, others), and pubertal Tanner
stage.
The assumption of linearity for continuously valued fac-
tors was evaluated using Generalized Additive Models
(GAM) [35], and relevant categorical variables were cre-
ated for those that were significantly non-linear at the
alpha = 0.05 level, and, for adiponectin, leptin and IGF-1
to minimize undue influence by extremely large values
[35]. Age at study (whole body analysis only), IL-6, time
elapsed since diagnosis (lumbar spine analysis only), and
calcium were categorized per non-linear relationship with
the outcomes. Category cut points were selected based on
visual inspection of predicted curves from GAM models,
and practical considerations regarding numbers of events
per category. Because of correlation between percent body
fat and leptin in both the whole body and lumbar spine
models, separate multivariable models were developed
including either leptin or percent body fat. Because of cor-
relation between hypogonadism and hypothyroidism in
the lumbar spine model, separate multivariable models
were developed including either hypothyroidism or hypo-
gonadism. Five models were evaluated: model 1: IGF-1
SDS, hypothyroidism and/or hypogonadism; model 2: lean
body mass, percent fat mass (or leptin), television/compu-
ter screen time, physical activity score, years since diagno-
sis and IL-6; model 3: milk, protein, fruits/vegetable and
daily total caloric intakes; model 4: protein, vitamin D,
z i n c ,c a l c i u m ,o m e g a - 3a n dd aily total caloric intakes;
model 5: radiation and steroid exposure. All models were
adjusted for age at study, sex, pubertal Tanner stage, and
ethnicity. All p-values are two-sided and those < 0.05 were
considered statistically significant, and those between 0.05
and 0.10 suggestive of association.
Results
Participant characteristics
We evaluated 527 participants, 319 childhood cancer sur-
vivors (148 females) aged 9-18 years and 208 controls (97
females) aged 9-18 years (Table 1). CCS were slightly
older than controls, howeverp u b e r t a lT a n n e rs t a g ew a s
similar between groups. CCS were generally of normal
stature, but were shorter than controls. Percent body fat
was higher and lean body mass lower in CCS, and there
were significantly more CCS with obesity (BMI ≥ 95%)
than controls.
By history or laboratory assessment on day of study, 2
CCS had type 1 diabetes mellitus, 2 had type 2 diabetes
mellitus, 31 had hypothyroidism (all on treatment with
normal free T4 levels on day of study), 22 had hypogo-
nadism, 4 had precocious puberty and 16 (5%) had
short stature (height less than 3
rd percentile for age and
gender). Thirty-six (13%) CCS were diagnosed with GH
deficiency by stimulation testing at the time of the study
and 34 (11%) were diagnosed prior to study entry. For
CCS, the average age at cancer diagnosis was 4.5 ± 0.2
years (range 0 - 12.5 years), and the average time since
treatment was 10.1 ± 0.2 years (range 4.3 - 17.8 years).
The median radiation dose in 31 CCS participants trea-
ted with CNS radiation was 2370 cGY (range 1800-5580
cGY). The median number of days of steroid treatment
in 133 CCS treated with steroids was 162 days (range 4-
302 days) and the median dose 7,520 mg/kg/day predni-
sone equivalents (range 200-15,250 mg/kg/day predni-
sone equivalents).
Bone mineral density
C C Sw e r es i g n i f i c a n t l ym o r el i k e l yt oh a v eb o t hw h o l e
body and lumbar spine BMD Z-score ≤ 1( F i g u r e1 )a s
compared to controls. The mean whole body BMD Z-
score and lumbar spine BMD Z-score were lower in CCS
vs. controls (unadjusted mean ± SEM: 0.3 ± 0.07 CCS vs.
0.6 ± 0.07 controls; p = 0.002, and -0.2 ± 0.06 CCS vs. 0.1
± 0.07 controls; p = 0.02 respectively); however, after
adjusting for height SDS there was no difference in whole
body or lumbar spine BMD Z-scores. There were very
few CCS (whole body N = 7 (2.3%), lumbar N = 11
(3.5%)) or controls (whole body = 0, lumbar = 0) with
BMD Z-scores ≤ -2. There was no evidence of differential
time-since diagnosis effects between subjects who were <
10 years compared to those ≥ 10 years at diagnosis.
Factors associated with reduced BMD in childhood cancer
survivors
In multivariable analysis, testing age, gender, ethnicity,
pubertal Tanner stage, IGF-1 SDS and hypothyroidism
and/or hypogonadism (model 1), CCS with hypogonad-
i s mw e r e9 . 1t i m e sm o r el i k e l yt oh a v ew h o l eb o d yB M D
Z-score ≤ -1 (95% CI: 3.3-25.3; p < 0.001) and 4.4 times
more likely to have lumbar spine BMD Z-score ≤ -1 (95%
CI: 1.7-11.4; p = 0.002). CCS with hypothyroidism were
2.9 times more likely to have lumbar spine BMD Z-score
≤ -1 (95% CI: 1.3-6.6; p = 0.012). Both hypogonadism and
hypothyroidism can cause short stature. Therefore, we
a d d e dh e i g h tS D St ot h em o d e l i n ga n df o u n ds i m i l a r
results. CCS with hypogonadism were 11.2 times more
l i k e l yt oh a v ew h o l eb o d yB M DZ - s c o r e≤ -1 (95% CI:
3.7-35.8; p < 0.001) and 4.3 times more likely to have
lumbar spine BMD Z-score ≤ -1 (95% CI: 1.6-11.8; p =
0.003). CCS with hypothyroidism were 2.8 times more
likely to have lumbar spine BMD Z-score ≤ -1 (95% CI:
1.2-6.7; p = 0.017). Neither GHD nor low IGF-1 SDS
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CCS(n = 319) Controls(n = 208)
Mean ± SE Mean ± SE P
Age at Study, years 14.5 ± 0.1 13.7 ± 0.2 < 0.001
Height, Z-score 0.1 ± 0.1 0.4 ± 0.1 < 0.001
Weight, Z-score 0.5 ± 0.1 0.6 ± 0.1 0.363
% Body Fat
† 28.1 ± 0.8 25.9 ± 0.9 0.007
Fat Mass, kg
† 16.5 ± 0.7 14.8 ± 0.8 0.024
Lean Body Mass, kg
† 38.5 ± 0.5 39.8 ± 0.6 0.015
IGF-1 SDS -1.24 ± 0.05 -1.04 ± 0.06 0.004
IL-6, pg/ml
† 1.4 ± 0.1 1.6 ± 0.3 0.505
Bone Age, years 14.5 ± 0.1 13.8 ± 0.2 < 0.001
Relative Bone Age 1.01 ± 0.01 1.01 ± 0.01 0.425
Tanner Score 3.6 ± 0.1 3.3 ± 0.1 0.068
Calcium Intake, mg/day 1280 ± 30 1257 ± 38 0.575
Vitamin D Intake, IU/day 331 ± 10 330 ± 12 0.968
Physical Activity Score, MET - minutes per week 58.6 ± 3.8 65.9 ± 4.9 0.191
N (Percent) N (Percent)
Screen time > 1 hr/day 225 (75.5) 147 (73.9) 0.680
0-1 hr/day 73 (24.5) 52 (26.1)
Ethnicity White/not Hispanic 274 (85.9) 194 (93.3) < 0.001
Others 45 (14.1) 14 (6.7)
Sex Males 171 (53.6) 111 (53.4) 0.956
Females 148(46.4) 97 (46.6)
BMI < 5% 9 (2.8) 4 (1.9) 0.495
≥ 5% to < 85% 210 (65.8) 137 (65.9) 0.995
≥ 85% to < 95% 42 (13.2) 43 (20.7) 0.031
≥ 95% 58 (18.2) 24 (11.5) 0.028
†Adjusted for age, sex, ethnicity, and pubertal Tanner stage
Relative Bone age = Bone age/actual age; MET = metabolic equivalent
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Figure 1 Whole body and lumbar spine bone deficits in childhood cancer survivors (CCS) compared to controls. Odds ratio (OR)
adjusted for sex, age-at-study, ethnicity (white-not-Hispanic, others), and pubertal Tanner stage are presented for BMD Z-score ≤ -1; OR for BMD
Z-score ≤ -2 unable to be calculated due to 0% prevalence in controls.
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Z-score ≤ -1. We were next interested in potential effects
of a sedentary lifestyle (obesity and low lean body mass)
and hormones influenced by adiposity (IL-6, adiponectin,
leptin) on bone density. Given the influence of GH defi-
ciency on lean body mass we evaluated the association
between lean body mass and GH deficiency; as there was
no significant association (p = 0.12) we did not include
GH deficiency in these models. In whole body multivari-
ate modeling of lean body mass, percent fat mass (or lep-
tin), television/computer screen time, physical activity
score, years since diagnosis and IL-6 (model 2), CCS with
higher IL-6 (> 2.5 pg/ml), two or more hours of television/
computer screen time per day, and lower lean body mass,
were more likely to have whole body BMD Z-score ≤ -1.
Percent body fat, adiponectin, years since diagnosis, and
physical activity score were not significantly associated
with whole body BMD Z-score ≤ -1 (Tables 2 and 3). The
addition of height SDS to this model did not change theses
associations and did not independently influence the odds
of BMD Z-score ≤ -1. In contrast to the results for whole
body BMD, in lumbar spine multivariate modeling, IL-6
and screen time were not associated with BMD. However,
even after adjusting for age, sex, and pubertal stage, both
decreases in physical activity score and lower lean body
mass (≤ 35 kg) were significantly associated with the odds
of lumbar spine BMD Z-score ≤ -1; after the addition of
height SDS to this model, the odds ratio for lean body
mass was attenuated (OR 2.9, 95%CI: 1.2-7.4; p = 0.02)
although height SDS did not independently influence the
odds of lumbar spine BMD Z-score ≤ -1.
Percent body fat and years since diagnosis were not
associated with lumbar spine BMD Z-score ≤ -1 (Tables
2 and 3). Leptin and percent body fat were strongly cor-
related; therefore, two models were built, one that
excluded leptin, and one that excluded percent body fat.
Similarly, when leptin was substituted for percent body
fat, it was not significantly associated with whole body
or lumbar spine BMD.
Of all the dietary and nutrient factors (model 3: milk,
protein, fruits/vegetable and daily total caloric intake
and model 4: protein, vitamin D, zinc, calcium, omega-3
and daily total caloric intake), only total protein was a
marginally significant predictor of whole body BMD Z-
score ≤ -1 (p = 0.055): the odds of whole body BMD Z-
score ≤ -1 were 3% lower for each additional 1 gram of
total protein intake. There were no significant associa-
tions in model 4.
Finally, the odds of whole body or lumbar spine BMD
Z-score ≤ -1 were significantly higher for both those
with CNS radiation and with other radiation, as com-
pared to those with no radiation (Tables 4 and 5); how-
ever when height SDS was added to the model the odds
of lumbar spine BMD Z-score ≤ -1 (but not for whole
body) were significantly attenuated for those who
received CNS or other radiation. The odds of lumbar
BMD Z-score ≤ -1 for those exposed to steroids were
almost twice that for those who did not receive steroids
(Tables 4 and 5); when height SDS was added to the
model the odds were significantly attenuated. The asso-
ciation between whole body BMD Z-score ≤ -1 and ster-
oids was not significant with or without height SDS in
the model. Subjects with a higher steroid exposure, a
more recent history of steroid exposure or a longer
duration of steroid exposure did not show larger BMD
deficits.
Discussion
In this study of childhood cancer survivors (CCS) < 18
y e a r so fa g ew h o l eb o d ya n dl u m b a rs p i n eB M Dd e f i -
ciencies (BMD Z-scores ≤ - 1 )w e r es i g n i f i c a n t l ym o r e
common than in a healthy sibling control group. This is
important for lifetime bone health, because children
with BMD Z-scores ≤ -1 are likely to have a lower peak
bone density that sets them up for early osteoporosis
and increased risk for fracture later in life. In addition,
even during childhood, lower BMD Z-scores are asso-
ciated with increased risk of fracture [33,34,36].
Table 2 Multivariable analysis in CCS of sedentary
lifestyle (obesity and low lean body mass) and hormones
influenced by adiposity (IL-6 and adiponectin) associated
with BMD Z-score ≤ -1
Outcome: Whole Body BMD Z-score ≤ -1
Categories OddsRatio 95%CI P
Age at study ≤ 16 years 1.0 --
> 16 years 2.5 0.8-8.1 0.125
Ethnicity Other 1.0 - -
White non-
Hispanic
1.7 0.5-6.9 0.420
Tanner stage, 1-5 One stage
increase
2.2 1.3-3.8 0.006
Sex Female 1.0 - -
Male 2.6 0.8-
10.0
0.137
Percent Body Fat 1% increase 0.95 0.9-1.0 0.070
Lean Body Mass 1 kg increase 0.85 0.8-0.9 <
0.001
Years Since Diagnosis 5-9 years 1.0 - -
> 9.0 years 2.3 0.9-6.3 0.080
IL-6 ≤ 2.5 ng/dl 1.0 - -
> 2.5 ng/dl 4.4 1.5-
12.9
0.007
Screen time*, per
day
0-1 hours 1.0 - -
≥ 2 hours 4.1 1.3-
18.6
0.033
Physical activity score and adiponectin were not significant factor s (p-value >
0.1) and were therefore removed from the model
*Screen time = television and computer screen time
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cross-sectional evidence to suggest “catch-up” in BMD
for participants treated at a younger, pre-pubertal, age
(< 10 years) and confirmed that hypogonadism is asso-
ciated with bone deficits in CCS. Finally, we identified
modifiable factors associated with lower BMD in CCS:
lower lean body mass (independent of GH deficiency
status), higher daily television/computer screen, lower
physical activity score, and higher IL-6. These risk fac-
tors may be targets for medical and lifestyle interven-
tions to increase bone density and decrease the risk of
early osteoporosis and fracture in children with CCS.
We found that lower lean body mass increased the like-
lihood of having a BMD Z-score ≤ -1 independent of the
influence of GH deficiency which was not associated with
lean body mass. CCS had significantly lower lean body
mass than controls; clinically we suspected this was at
least in part due to decreased physical activity in CCS;
however we did not find a difference in physical activity
score between CCS and controls. This may be due to the
limitations of quantifying physical activity by question-
naire. Other studies in healthy pediatric populations have
shown that increased muscle mass is associated with
increased bone mineral content, density, and estimated
bone strength [37-40] and that lean body mass, along
with male gender and physical activity, can explain up to
37% of total variance in BMD in healthy, prepubertal
children [41]. Therefore, these reports suggest that inter-
ventions aimed at increasing lean body mass may
improve bone density and strength in CCS.
Although physical activity was no different between
CCS and controls, lower physical activity in CCS
increased the likelihood of having a BMD Z-score ≤ -1.
The long-term beneficial impact of increased physical
activity on bone was demonstrated in a twin study show-
ing that twins with higher levels of leisure time physical
Table 4 Multivariable analysis of cancer treatment factors
associated with BMD Z-score ≤ -1
Outcome: Whole body BMD Z-score ≤ -1.
Category OddsRatio 95%CI P
Age at Study ≤ 16 years 1.0 - -
> 16 years 2.0 0.8-5.3 0.177
Ethnicity Other 1.0 - -
White non-
Hispanic
0.9 0.3-2.9 0.800
Tanner stage, 1-5 One stage
increase
0.9 0.6-1.4 0.666
Sex Females 1.0 - -
Males 1.2 0.5-2.5 0.704
Radiation
Exposure
None 1.0 - -
CNS Radiation 7.9 3.0-
20.8
<
0.001
Other Radiation 5.7 2.3-
13.9
<
0.001
Steroid exposure was not a significant factor (p-value > 0.1) and was therefore
removed from the model
Table 3 Multivariable analysis in CCS of sedentary lifestyle (obesity and low lean body mass) and hormones
influenced by adiposity (IL-6 and adiponectin) associated with BMD Z-score ≤ -1
Outcome: Lumbar spine BMD Z-score ≤ -1
Categories OddsRatio 95%CI P
Age at Study 1 year increase 2.2 1.7-3.0 < 0.001
Ethnicity Other 1.0 - -
White non-Hispanic 2.6 0.9-9.1 0.104
Tanner, 1-5 One stage increase 0.4 0.2-0.7 < 0.001
Sex Female 1.0 - -
Male 1.6 0.7-3.4 0.270
Lean Body Mass > 35 kg 1.0 - -
≤ 35 kg 4.1 1.8-9.6 < 0.001
Percent Body Fat 1% increase 0.97 0.94-1.0 0.088
Physical Activity Score One unit increase 0.99 0.99-1.0 0.042
Years since diagnosis, IL-6, adiponectin, and screen time were not significant factors (p-value > 0.1) and were therefore removed from the model
Table 5 Multivariable analysis of cancer treatment factors
associated with BMD Z-score ≤ -1
Outcome: Lumbar spine BMD Z-score ≤ -1.
Category OddsRatio 95%CI P
Age at Study ≤ 16 years 1.0 - -
> 16 years 3.1 1.4-7.1 0.006
Ethnicity Other 1.0 - -
White non-Hispanic 2.2 0.9-6.7 0.135
Tanner stage, 1-5 One stage increase 0.7 0.5-0.9 0.015
Sex Female 1.0 - -
Male 1.1 0.6-1.9 0.732
Radiation Exposure None 1.0 - -
Cranial Radiation 2.5 1.0-5.7 0.040
Other Radiation 2.4 1.0-5.5 0.041
Steroid Exposure No 1.0 - -
Yes 1.9 1.0-3.5 0.042
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and compression strength of bone [42]. Increased physi-
cal activity has also been shown to improve bone health
in healthy children [43]. Studies on the relationship
between physical activity and measures of bone health in
CCS have reported either positive associations, similar to
our data [2,6,15,32], or no associations [4,7,21,44]. Some
of the variability in results is likely related to limitations
of activity questionnaires to accurately measure activity
level and/or intensity. Adding accelerometers to ques-
tionnaires to measure physical activity in CCS uncovered
a positive correlation between activity levels and both
whole body BMD and estimated volumetric lumbar spine
BMD [2] and may provide a more accurate assessment of
daily activity level.
Television/computer screen time is used as a surrogate
measure of physical activity [45]. The present cohort was
divided between CCS who watched television/computer
screen for ≥ 2 hours per day versus < 2 hours per day;
the CCS with the higher television/computer screen were
more likely to have whole body BMD Z-scores ≤ -1. This
is similar to a prior report that time spent on television
and computers negatively correlated with BMD Z-scores
in CCS [5]. In contrast, no association between viewing
time and bone measures were found in another study of
CCS [3]. The equivocal findings again may be due to lim-
itations in using television viewing time as a surrogate
measure for activity. In addition, intensity of exercise is
not accounted for when simply quantifying television/
computer screen time.
Higher levels of the inflammatory cytokine IL-6 were
associated with a BMD Z-score ≤ -1 in this cohort of
CCS. Although we did not measure markers of bone
turnover, other studies have shown that IL-6 can induce
osteoclastogenesis [46], increase bone resorption [47],
and inhibit bone formation by osteoblasts [48]. Studies in
adult men and women, before and after menopause, have
shown associations between higher levels of IL-6 and
osteoporosis [49-51], and baseline IL-6 levels have pre-
dicted bone loss over a 3 year period in older adults [52].
Higher levels of IL-6 have also been shown to correlate
with osteoporosis and other bone deficits in patients with
chronic inflammatory diseases such as rheumatoid arthri-
tis [53] and inflammatory bowel disease [54], as well as
patients who underwent HCT [55-59]. The current study
is the first to report such an association in CCS who have
not received HCT.
A limitation of this study is that the bone density data
were collected by DXA. DXA provides a 2-dimensional
image that can result in a falsely decreased BMD in chil-
dren who are small for their age simply due to small
bone size [60-63]. A potential example of this in our
study was the finding that mean BMD Z-scores were sig-
nificantly different between CCS and healthy siblings
before adjustment for height SDS, but not significantly
different after adjusting for height SDS. However, CCS
were on average shorter than the healthy siblings and so
it is impossible to distinguish by DXA measurements
whether the influence of height SDS is due to DXA
underestimating BMD in shorter individuals or simply
that height SDS is acting as an indicator of being in the
CCS group. The mean height in our CCS cohort was nor-
mal (0.1 ± 01 SDS) therefore we would not expect a sig-
nificant underestimation of BMD by DXA. DXA is also
limited in that it cannot distinguish between cortical and
trabecular bone or estimate bone strength. Future studies
of bone health in CCS should consider performing per-
ipheral quantitative computer tomography (pQCT) scans
to limit the impact of short stature on BMD and evaluate
potential variation in impact on cortical versus trabecular
bone. DXA is clinically useful because of low radiation
exposure, short time required for scanning, and ample
amount of scientific literature in pediatric populations.
Importantly, studies have shown that not only low BMD
Z-score, but any decrease in BMD Z-score predisposes
children to an increased risk of fractures [33,34]. An
additional limitation is that markers of bone turnover
and vitamin D levels were not measured; vitamin D
intake was used as a surrogate marker for 25-OH vitamin
D level. Finally, in this cross-sectional study it is not pos-
sible to make any inference on causality. Despite these
limitations, the study documents the presence of mild
bone deficits in childhood cancer survivors (even before
they reach adulthood) and identifies potentially modifi-
able factors associated with bone deficits.
Conclusions
In conclusion, this is the first study comparing bone
health measures between CCS and a sibling control
group during childhood. We found that CCS had lower
lumbar spine and total body BMD than the controls, and
that although reported activity levels were no different
between groups, CCS had lower lean body mass than the
controls. Within the CCS group, the results show that
lower lean body mass, lower levels of physical activity,
higher daily television viewing time, higher IL-6 levels,
hypogonadism and exposure to radiation or steroids
increased the likelihood of having a BMD Z-score ≤ -1.
In addition, contrary to what we expected, treatment
before puberty and length of time since treatment did
not influence risk of having bone deficits. A BMD Z-
score ≤ -1 is expected to increase both the current and
lifetime risk of fracture. Although we have not shown
causality between any of these measures and bone health,
prospective data in other populations support the bone
health benefits of increasing lean body mass through
activity and resistance exercises. Finally, our finding of
the association of IL-6 with measures of bone health
Polgreen et al. BMC Pediatrics 2012, 12:40
http://www.biomedcentral.com/1471-2431/12/40
Page 7 of 9identifies a novel potential treatment target to prevent
osteoporosis in CCS and requires prospective studies to
determine what if any impact modification of this inflam-
matory variable will have on bone health in CCS.
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